Lv11
90 积分 2023-08-03 加入
Emerging Therapeutic Approaches for Anemia in Myelofibrosis
7小时前
已完结
A first-in-class JAK/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study
21天前
已完结
Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future
4个月前
已完结
Baseline Erythropoietin Level Predicts Luspatercept Response in Chinese Patients with Myelodysplastic Syndrome: A Propensity Score-Matched Analysis
4个月前
已完结
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group
4个月前
已完结
MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial
5个月前
已关闭
Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study
5个月前
已关闭
Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors
5个月前
已完结
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
5个月前
已关闭
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
5个月前
已完结
皖公网安备34019202002308
